Yes. Consumer taste panels involving sensitive consumers confirmed that pork from immunocastrated pigs is indistinguishable from pork from physically castrated animals in both aroma and flavor. Immunocastration substantially reduces androstenone and skatole, the primary compounds responsible for boar taint, matching the rate of physical castration. No withdrawal period is required, and the vaccine leaves no residues in the meat. As noted above, the product contains no hormones and does not alter the animal's genetics, it works entirely through a temporary immune response.

This is directly addressed by the certified verification program that comes with the product. For Zoetis’ Improvest, the only option currently available in the U.S., the program includes trained and certified vaccination technicians, a proprietary tracking system covering prescriptions, two-dose timing, and in-barn quality assurance inspections, and a full audit conducted two weeks after the second dose to verify compliance. A quality assurance certificate is delivered with the animals at market. 

Consumer awareness of castration practices in pork production is very low: a survey Innovate Animal Ag conducted in December 2025 found that 83% of U.S. respondents were unaware that male pigs are castrated at all. When informed, consumers rated immunocastration as the most humane option available. Major export markets including Japan, Mexico, South Korea, and Canada, where U.S. producers compete directly with Brazil, already accept immunocastrated pork without restriction. For retailers with sustainability commitments, immunocastration also offers a measurable reduction in Scope 3 emissions tied to feed efficiency gains. Importantly, because the product is a vaccine with no hormones, growth promotants, or genetic modifications involved, it avoids many common consumer concerns.

Accidental self-injection is a known risk that requires proper handling protocols. Because the vaccine acts across mammals, two doses could temporarily suppress testicular function in a person. This risk is real but manageable: only trained and certified technicians administer the product, and the program includes specific safety training on injection technique and handling procedures. The expected immunological response from an accidental single injection reverses within weeks, and documented incidents have been rare. Proper needle guards, handling protocols, and operator training are standard components of any certified immunocastration program. Other technologies under development such as feed-based administration could completely solve this problem.

Yes. By suppressing estrus, immunocastration improves daily weight gain and uniformity, adding up to 7 lbs of hot carcass weight per gilt. It also promotes the deposition of firmer, more saturated fat — an advantage for products like bacon. Because immunocastrated gilts are visually indistinguishable from untreated gilts after slaughter, the technology can be introduced without changes to how carcasses are processed or labeled, making it a lower-friction entry point for packers and producers exploring the technology for the first time.